Ligand Pharmaceuticals (LGND) Revenue (2010 - 2026)

Ligand Pharmaceuticals has reported Revenue for 17 years, with the latest figure at $51.7 million in Q1 2026.

• Quarterly Revenue rose 14.09% year-over-year to $51.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $274.5 million (up 51.24% YoY) and the FY2025 annual result came in at $268.1 million, up 60.4% from the prior year.
• Revenue retreated to $51.7 million in Q1 2026 per LGND's latest filing, from $59.7 million in the prior quarter.
• Over five years, Revenue peaked at $115.5 million in Q3 2025 and troughed at $26.4 million in Q2 2023.
• A 5-year average of $47.9 million and a median of $45.3 million in 2025 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2025: Revenue tumbled 47.4% in 2023, then jumped 122.85% in 2025.
• Over 5 years, Revenue stood at $50.4 million in 2022, then sank by 44.22% to $28.1 million in 2023, then soared by 52.35% to $42.8 million in 2024, then soared by 39.37% to $59.7 million in 2025, then fell by 13.31% to $51.7 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $51.7 million, $59.7 million, and $115.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.